<DOC>
	<DOCNO>NCT01274208</DOCNO>
	<brief_summary>Study objective : - Investigate anti-HCV response patient Gaucher disease ( GD ) - Define potential role high level Glucocerebroside immune system Study hypothesis : High level Glucocerebroside use tool antiviral treatment hepatitis C potentiate immune response natural killer T cell dendritic cell</brief_summary>
	<brief_title>Examining Immune Response Patients With Gaucher Disease Hepatitis C</brief_title>
	<detailed_description>Gaucher disease common glycolipid storage disorder , cause reduced activity lysosomal enzyme glucocerebrosidase , lead accumulation substrate , glucocerebroside ( GC ) , cell reticulo-endothelial system . One hallmark GD great phenotypic heterogeneity variable presentation symptom , begin lethal variant infant die near birth hydrops fetalis ichthyoids one extreme totally asymptomatic individual without physical laboratory abnormality extreme . This autosomal recessive disease pan-ethnic , especially prevalent among Ashkenazi Jews . From 300 different mutation report glucocerebrosidase gene , five account 98 % disease-producing allele . Of mutation , N370S ( 1226G ) occur 1 17 Ashkenazi individual , lead disease frequency 1:850 ethnic group . The high prevalence single mutation among Ashkenazi Jews existence two additional rare inherit lysosomal glycolipid storage disease , Tay Sachs Nieman Pick , high prevalence within ethnic group believe cause selective advantage . Available genetic data consistent founder effect ( 4 ) whereas nature advantage identify . The aim study investigate anti-HCV immune response patient GD attempt define potential role high level GC immune system antiviral immunity . Study importance : The host metabolic background exert profound effect antiviral immunity , may influence clinical course chronic HCV infection . The accumulation GC patient GD may provide selective evolutionary advantage patient . Glucocerebroside recently test human trial show effective alter NKT- dependent metabolic pathway , insulin resistance , associate liver injury . The present study examine capability Glucocerebroside use tool antiviral treatment hepatitis C potentiate immune response natural killer T cell dendritic cell . Statistical Analysis : Data present mean Â± standard deviation ( SD ) . The Kruskal Wallis non-parametric ANOVA test use identify difference study group . The student t-test non-parametric Mann-Whitney test use compare quantitative variable study group appropriate ; P &lt; 0.05 consider significant .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Patients Gaucher disease Patients hepatitis C without Gaucher disease Individuals patient without Gaucher disease hepatitis C Individuals patient sign approval research Men woman 18 &lt; year age , pregnant woman Inabillity give approval research Acute liver disease alter lab result , : Rt . congestive heart failure severe infection , inflammation , medication : Statins , Isoniazid , Amiodarone Patients receive treatment hepatitis C : Interferon , Pegylated interferon , Ribavirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Gaucher disease , Hepatitis C , Glucocerebroside immunity</keyword>
</DOC>